Literature DB >> 20159260

Partial improvement of solar urticaria after omalizumab.

Kirk H Waibel, Drew A Reese, Robert G Hamilton, Richard L Devillez.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20159260     DOI： 10.1016/j.jaci.2009.11.007

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  9 in total

Review 1.  Review of Physical Urticarias and Testing Methods.

Authors:  Mario Sánchez-Borges; Luis González-Aveledo; Fernan Caballero-Fonseca; Arnaldo Capriles-Hulett
Journal:  Curr Allergy Asthma Rep       Date:  2017-08       Impact factor: 4.806

Review 2.  What to do with refractory urticaria patients.

Authors:  Allen P Kaplan
Journal:  Curr Allergy Asthma Rep       Date:  2011-06       Impact factor: 4.806

Review 3.  Physical urticaria.

Authors:  Marina Abajian; Agnieszka Młynek; Marcus Maurer
Journal:  Curr Allergy Asthma Rep       Date:  2012-08       Impact factor: 4.806

Review 4.  Omalizumab: Anti-IgE therapy in allergy.

Authors:  Matthias Volkmar Kopp
Journal:  Curr Allergy Asthma Rep       Date:  2011-04       Impact factor: 4.806

5.  Omalizumab for chronic urticaria: a case series and overview of the literature.

Authors:  Ilya Ivyanskiy; Carsten Sand; Simon Francis Thomsen
Journal:  Case Rep Dermatol       Date:  2012-01-30

6.  Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells.

Authors:  Eva Serrano-Candelas; Rubén Martínez-Aranguren; Olga Vega; Gabriel Gastaminza; Joan Bartra; Maria Teresa Audicana; Jorge M Núñez-Córdoba; Jaime Algorta; Antonio Valero; Margarita Martin; Marta Ferrer
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

7.  Diagnosis and treatment of urticaria and angioedema: a worldwide perspective.

Authors:  Mario Sánchez-Borges; Riccardo Asero; Ignacio J Ansotegui; Ilaria Baiardini; Jonathan A Bernstein; G Walter Canonica; Richard Gower; David A Kahn; Allen P Kaplan; Connie Katelaris; Marcus Maurer; Hae Sim Park; Paul Potter; Sarbjit Saini; Paolo Tassinari; Alberto Tedeschi; Young Min Ye; Torsten Zuberbier
Journal:  World Allergy Organ J       Date:  2012-11       Impact factor: 4.084

8.  Omalizumab, an anti-immunoglobulin E antibody: state of the art.

Authors:  Cristoforo Incorvaia; Marina Mauro; Marina Russello; Chiara Formigoni; Gian Galeazzo Riario-Sforza; Erminia Ridolo
Journal:  Drug Des Devel Ther       Date:  2014-02-07       Impact factor: 4.162

9.  Long term treatment with omalizumab in adolescent with refractory solar urticaria.

Authors:  Mauro Iannelli; Stefano Passanisi; Giuseppe Crisafulli; Stefania Arasi; Lucia Caminiti; Giuseppina Zirilli; Giovanni B Pajno
Journal:  Ital J Pediatr       Date:  2021-09-28       Impact factor: 2.638
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.